Humphreys M J, Moon R P, Klinder A, Fowler S D, Rupp K, Bur D, Ridley R G, Berry C
Cardiff School of Biosciences, Cardiff University, P.O. Box 911, Cardiff, UK.
FEBS Lett. 1999 Dec 10;463(1-2):43-8. doi: 10.1016/s0014-5793(99)01597-5.
The gene encoding an aspartic proteinase precursor (proplasmepsin) from the rodent malaria parasite Plasmodium berghei has been cloned. Recombinant P. berghei plasmepsin hydrolysed a synthetic peptide substrate and this cleavage was prevented by the general aspartic proteinase inhibitor, isovaleryl pepstatin and by Ro40-4388, a lead compound for the inhibition of plasmepsins from the human malaria parasite Plasmodium falciparum. Southern blotting detected only one proplasmepsin gene in P. berghei. Two plasmepsins have previously been reported in P. falciparum. Here, we describe two further proplasmepsin genes from this species. The suitability of P. berghei as a model for the in vivo evaluation of plasmepsin inhibitors is discussed.
编码来自啮齿类疟原虫伯氏疟原虫天冬氨酸蛋白酶前体(原质蛋白酶)的基因已被克隆。重组伯氏疟原虫原质蛋白酶可水解一种合成肽底物,而这种切割作用可被通用天冬氨酸蛋白酶抑制剂异戊酰胃蛋白酶抑制剂以及Ro40 - 4388(一种用于抑制人类疟原虫恶性疟原虫原质蛋白酶的先导化合物)所抑制。Southern印迹法检测到伯氏疟原虫中仅存在一个原质蛋白酶基因。此前已报道恶性疟原虫中有两种原质蛋白酶。在此,我们描述了该物种的另外两个原质蛋白酶基因。文中还讨论了伯氏疟原虫作为原质蛋白酶抑制剂体内评估模型的适用性。